UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. Commission file number 001-08789 American Shared Hospital Services (Exact name of registrant as specified in its charter) Cal ...

American Shared Hospital Services (NYSE:AMS) Q1 2023 Results Conference Call May 12, 2023 12:00 PM ET Company Participants Stephanie Prince - PCG Advisory Ray Stachowiak - Executive Chairman Peter Gaccione - Chief Executive Officer Bob Hiatt - Chief Financial Officer Operator Good morning. And welcome to the American Shared Hospital Services First Quarter 2023 Earnings Conference Call. All participants will be in listen only mode [Operator Instructions]. Please note that this event is being recorded. I wou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________. Commission file number 001-08789 American Shared Hospital Services (Exact name of registrant as specified in its charter) Ca ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock No Par Value AMS NYSEAMER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Mark One) FORM 10-K ☒ Annual Report Pursuant To Section 13 or 15(d) Of The Securities Exchange Act Of 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022 or ☐ Transition Report Pursuant To Section 13 or 15(D) Of The Securities Exchange Act Of 1934 For The Transition Period From _______________To___________ ...

American Shared Hospital Services (NYSE:AMS) Q4 2022 Earnings Conference Call March 24, 2023 1:00 PM ET Company Participants Stephanie Prince - PCG Advisory Raymond Stachowiak - Executive Chairman Peter Gaccione - CEO Craig Tagawa - CFO Conference Call Participants Tony Kamin - Eastwood Partners Anthony Marquez - Private Investor Tony Kamin - Eastwood Partners Operator Hello, and welcome to the American Shared Hospital Services Fourth Quarter 2022 Earnings Conference Call. [Operator Instructions] Please not ...

American Shared Hospital Services (NYSE:AMS) Q3 2022 Earnings Conference Call November 10, 2022 3:00 PM ET Company Participants Stephanie Prince - PCG Advisory Raymond Stachowiak - CEO Craig Tagawa - CFO Peter Gaccione - COO Conference Call Participants Tony Kamin - Eastwood Partners Operator Good day, and welcome to the American Shared Hospital Services Third Quarter 2022 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over ...

American Shared Hospital Services (NYSE:AMS) Q2 2022 Earnings Conference Call August 12, 2022 12:00 PM ET Company Participants Stephanie Prince - Investor Relations Ray Stachowiak - Chief Executive Officer Alexis Wallace - Chief Accounting Officer Craig Tagawa - President, Chief Operating Officer and Chief Financial Officer Conference Call Participants Tony Kamin - Eastwood Partners Operator Good day and welcome to the American Shared Hospital Services Second Quarter 2022 Earnings Call. [Operator Instructio ...

Financial Data and Key Metrics Changes - Total revenue increased by 11% year-over-year to $4.8 million, which is approximately 3% higher than the previous quarter's revenue of $4.7 million [5][9] - Net income for Q1 2022 was $269,000 or $0.04 per diluted share, compared to $29,000 or $0.00 per diluted share in Q1 2021 [6][11] - Adjusted EBITDA increased by 20.1% to $1,922,000 for Q1 2022 compared to $1,600,000 in Q1 2021 [11] Business Line Data and Key Metrics Changes - Revenue from the proton therapy system increased by 33.2% to $2,039,000 in Q1 2022 compared to $1,531,000 in Q1 2021, with total proton therapy fractions rising by 32.3% to 1,628 [9][13] - Revenue from Gamma Knife operations decreased by 2.9% to $2,808,000 in Q1 2022, with procedures down by 7.3% to 329 [9][14] Market Data and Key Metrics Changes - The company announced a new international location in Puebla, Mexico, which is expected to start operations in early 2023, pending regulatory approvals [6][7] - The current ratio increased to 3.2 times compared to 1.6 times at March 31, 2021, indicating improved liquidity [15] Company Strategy and Development Direction - The company is expanding its sales team and product offerings, including linear accelerators and MR/LINACs, to enhance its market presence and meet client needs [7][28] - The management is actively pursuing more proton beam business, leveraging relationships and financial resources to support healthcare systems in acquiring advanced cancer treatment technologies [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth potential, citing a strong base for future profitability and the ability to leverage new business opportunities as the pandemic wanes [6][30] - The technology for proton beam therapy remains relevant and desirable among healthcare systems, with management indicating a commitment to pursue this market aggressively [20][21] Other Important Information - Selling and administrative costs increased by 21.7% to $1,319,000 due to higher legal fees associated with new business opportunities [10][15] - Interest expense decreased by 43.1% to $148,000, reflecting the benefits of a debt refinancing completed in April 2021 [10][15] Q&A Session Summary Question: Proton beam therapy results and future placements - The management confirmed that the technology remains relevant and they are ramping up efforts to pursue more proton beam business, supported by an expanded sales team and financial resources [20][21] Question: Client satisfaction with current proton beam - Management indicated that the current client is very satisfied and would serve as a good reference for future business [22][23] Question: Manufacturer collaboration for proton beam systems - Management stated they are open to working with various manufacturers and are not limited to one supplier, which enhances their market opportunities [25][26] Question: Expanded product offerings and impact - Management detailed the expansion of their product line to include various radiation therapy equipment, which is expected to create new business opportunities, exemplified by the joint venture in Puebla, Mexico [28][29]